Buprenorphine Injection
Generic name: Pronounced as (byoo pre nor' feen)
Medical Content Reviewed By HelloPharmacist Staff
Last Revised - 05/15/2023
On this page
- Why is this medication prescribed?
- How should this medicine be used?
- Other uses for this medicine
- What special precautions should I follow?
- What special dietary instructions should I follow?
- What should I do if I forget a dose?
- What side effects can this medication cause?
- What should I do in case of OVERDOSE?
- What OTHER INFORMATION should I know?
- Drug interactions
Notice:
FDA Drug Safety Communication:
[Posted 4/13/2023]
-
As part of its ongoing efforts to address the nation's opioid crisis, FDA is requiring several updates to the prescribing information of opioid pain medicines. The changes are being made to provide additional guidance for safe use of these drugs while also recognizing the important benefits when used appropriately. The changes apply to both immediate-release (IR) and extended-release/long-acting preparations (ER/LA).
-
Updates to the IR opioids state that these drugs should not be used for an extended period unless the pain remains severe enough to require an opioid pain medicine and alternative treatment options are insufficient, and that many acute pain conditions treated in the outpatient setting require no more than a few days of an opioid pain medicine.
-
Updates to the ER/LA opioids recommend that these drugs be reserved for severe and persistent pain requiring an extended period of treatment with a daily opioid pain medicine and for which alternative treatment options are inadequate.
-
A new warning is being added about opioid-induced hyperalgesia (OIH) for both IR and ER/LA opioid pain medicines. This includes information describing the symptoms that differentiate OIH from opioid tolerance and withdrawal.
-
Information in the boxed warning for all IR and ER/LA opioid pain medicines will be updated and reordered to elevate the importance of warnings concerning life-threatening respiratory depression, and risks associated with using opioid pain medicines in conjunction with benzodiazepines or other medicines that depress the central nervous system (CNS).
-
Other changes will also be required in various other sections of the prescribing information to educate clinicians, patients, and caregivers about the risks of these drugs.
IMPORTANT WARNING
Buprenorphine extended-release injection is only available through a special distribution program called Sublocade REMS. Your doctor and your pharmacy must be enrolled in this program before you can receive buprenorphine injection. Ask your doctor for more information about this program and how you will receive your medication.
Keep all appointments with your doctor and the laboratory. Your doctor may order certain tests before and during your treatment to check your body's response to buprenorphine extended-release injection.
Your doctor or pharmacist will give you the manufacturer's patient information sheet (Medication Guide) when you begin treatment with buprenorphine extended-release injection and each time you refill your prescription. Read the information carefully and ask your doctor or pharmacist if you have any questions. You can also visit the Food and Drug Administration (FDA) website (http://www.fda.gov/Drugs/DrugSafety/ucm085729.htm) to obtain the Medication Guide.
Why is this medication prescribed?
Buprenorphine extended-release injection is used to treat opioid dependence (addiction to opioid drugs, including heroin and narcotic painkillers) in people who have received buccal or sublingual buprenorphine for at least 7 days. Buprenorphine extended-release injection is in a class of medications called opiate partial agonists. It works to prevent withdrawal symptoms when someone stops taking opioid drugs by producing similar effects to these drugs.
How should this medicine be used?
Buprenorphine extended-release (long-acting) injection comes as a solution (liquid) to be injected subcutaneously (just under the skin) by a health care provider into the stomach area. It is usually given once monthly with at least 26 days in between doses. Each buprenorphine injection slowly releases the drug into your body over a month.
After you receive a dose of buprenorphine extended-release injection, you may notice a lump at the injection site for several weeks, but it should decrease in size over time. Do not rub or massage the injection site. Be sure that your belt or waistband does not put pressure on the place where the medication was injected.
Your doctor may increase or decrease your dose depending on how well the medication works for you, and any side effects you experience. Be sure to tell your doctor how you are feeling during your treatment with buprenorphine extended-release injection.
If buprenorphine extended-release is to be discontinued, your doctor will probably decrease your dose gradually. You may experience withdrawal symptoms including restlessness, teary eyes, sweating, chills, widening of the pupils (black circles in the middle of the eyes), irritability, anxiety, backache, weakness, stomach cramps, difficulty falling asleep or staying asleep, nausea, loss of appetite, vomiting, diarrhea, fast breathing, or fast heartbeat. These withdrawal symptoms may occur 1 month or longer after your last buprenorphine extended-release injection dose.
Other uses for this medicine
This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.
What special precautions should I follow?
Before receiving buprenorphine injection,
-
tell your doctor and pharmacist if you are allergic to buprenorphine, any other medications, or any of the ingredients in buprenorphine injection. Ask your pharmacist or check the Medication Guide for a list of the ingredients.
-
tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: antihistamines; benzodiazepines such as such as alprazolam (Xanax), chlordiazepoxide (Librium, in Librax), clonazepam (Klonopin), diazepam (Valium), estazolam, flurazepam, lorazepam (Ativan), oxazepam, temazepam (Restoril), triazolam (Halcion); carbamazepine (Carbatrol, Tegretol, Teril, others); diuretics ('water pills'); erythromycin (E.E.S., Eryc, PCE, others); HIV medications such as atazanavir (Reyataz, in Evotaz), delavirdine (Rescriptor), efavirenz (Sustiva, in Atripla), etravirine (Intelence), indinavir (Crixivan), nevirapine (Viramune), ritonavir (Norvir, in Kaletra), and saquinavir (Invirase); certain medications for irregular heartbeat including amiodarone (Nexterone, Pacerone), disopyramide (Norpace), dofetilide (Tikosyn), procainamide (Procanbid), quinidine (in Nuedexta), and sotalol (Betapace, Betapace AF, Sorine); medications for glaucoma, mental illness, motion sickness, Parkinson's disease, ulcers, or urinary problems; ketoconazole, other medications for pain; medications for migraine headaches such as almotriptan (Axert), eletriptan (Relpax), frovatriptan (Frova), naratriptan (Amerge), rizatriptan (Maxalt), sumatriptan (Imitrex, in Treximet), and zolmitriptan (Zomig); muscle relaxants; phenobarbital; phenytoin (Dilantin, Phenytek); rifampin (Rifadin, Rimactane); sedatives; sleeping pills; 5HT3 serotonin blockers such as alosetron (Lotronex), dolasetron (Anzemet), granisetron (Kytril), ondansetron (Zofran, Zuplenz), or palonosetron (Aloxi); selective serotonin-reuptake inhibitors such as citalopram (Celexa), escitalopram (Lexapro), fluoxetine (Prozac, Sarafem, in Symbyax), fluvoxamine (Luvox), paroxetine (Brisdelle, Prozac, Pexeva), and sertraline (Zoloft); serotonin and norepinephrine reuptake inhibitors such as duloxetine (Cymbalta), desvenlafaxine (Khedezla, Pristiq), milnacipran (Savella), and venlafaxine (Effexor); tramadol; tranquilizers; trazodone; or tricyclic antidepressants ('mood elevators') such as amitriptyline, clomipramine (Anafranil), desipramine (Norpramin), doxepin (Silenor), imipramine (Tofranil), nortriptyline (Pamelor), protriptyline (Vivactil), and trimipramine (Surmontil). Also tell your doctor or pharmacist if you are taking or receiving the following monoamine oxidase (MAO) inhibitors or if you have stopped taking them within the past two weeks: isocarboxazid (Marplan), linezolid (Zyvox), methylene blue, phenelzine (Nardil), selegiline (Eldepryl, Emsam, Zelapar), or tranylcypromine (Parnate). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with buprenorphine, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.
-
tell your doctor if you or a family member drinks or has ever drunk large amounts of alcohol or have or have ever had prolonged QT syndrome (condition that increases the risk of developing an irregular heartbeat that may cause loss of consciousness or sudden death). Also, tell your doctor if you have or have ever had low levels of potassium or magnesium in the blood; heart failure; a slow or irregular heartbeat; chronic obstructive pulmonary disease (COPD; a group of diseases that affect the lungs and airways); other lung diseases; a head injury; a brain tumor; any condition that increases the amount of pressure in your brain; adrenal problems such as Addison's disease (condition in which the adrenal gland produces less hormone than normal); benign prostatic hypertrophy (BPH, enlargement of the prostate gland); difficulty urinating; hallucinations (seeing things or hearing voices that do not exist); a curve in the spine that makes it hard to breathe; or thyroid, gallbladder, or liver disease.
-
tell your doctor if you are pregnant or plan to become pregnant. If you receive buprenorphine extended-release injection regularly during your pregnancy, your baby could experience life-threatening withdrawal symptoms after birth. Tell your baby's doctor right away if your baby experiences any of the following symptoms: irritability, hyperactivity, abnormal sleep, high-pitched cry, uncontrollable shaking of a part of the body, vomiting, diarrhea, or failure to gain weight.
-
tell your doctor if you are breastfeeding. Tell your baby's doctor right away if your baby is sleepier than usual or has trouble breathing while you are receiving this medication.
-
you should know that this medication may decrease fertility in men and women. Talk to your doctor about the risks of using buprenorphine extended-release injection.
-
if you are having surgery, including dental surgery, tell the doctor or dentist that you are receiving buprenorphine extended-release injection.
-
you should know that buprenorphine extended-release injection may make you drowsy. Do not drive a car or operate machinery until you know how this medication affects you.
-
you should not drink alcohol or use street drugs during your treatment. Drinking alcohol, taking prescription or nonprescription medications that contain alcohol, or using street drugs during your treatment with buprenorphine injection increases the risk that you will experience serious and life-threatening breathing problems.
-
you should know that buprenorphine may cause dizziness, lightheadedness, and fainting when you get up too quickly from a lying position. To avoid this problem, get out of bed slowly, resting your feet on the floor for a few minutes before standing up.
-
you should know that buprenorphine may cause constipation. Talk to your doctor about changing your diet or using other medications to prevent or treat constipation while you are using buprenorphine injection.
What special dietary instructions should I follow?
Unless your doctor tells you otherwise, continue your normal diet.
What should I do if I forget a dose?
If you miss a scheduled buprenorphine extended-release injection dose, you should call your doctor to receive the dose as soon as possible. Your next dose should be given at least 26 days later.
What side effects can this medication cause?
-
Buprenorphine extended-release injection may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:
-
nausea
-
vomiting
-
headache
-
fatigue
-
pain, itching, swelling, discomfort, redness, bruising, or bumps in the injection site
-
-
Some side effects can be serious. If you experience any of these symptoms call your doctor immediately or get emergency medical treatment:
-
difficulty breathing
-
agitation, hallucinations (seeing things or hearing voices that do not exist), fever, sweating, confusion, fast heartbeat, shivering, slurred speech, severe muscle stiffness or twitching, loss of coordination, nausea, vomiting, or diarrhea
-
nausea, vomiting, loss of appetite, weakness, or dizziness
-
inability to get or keep an erection
-
irregular menstruation
-
decreased sexual desire
-
rash
-
hives
-
itching
-
slurred speech
-
blurred vision
-
changes in heartbeat
-
pain in the upper right part of the stomach
-
yellowing of the skin or eyes
-
dark-colored urine
-
light-colored stools
-
-
Buprenorphine extended-release injection may cause other side effects. Call your doctor if you have any unusual problems while receiving this medication.
-
If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online (http://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).
What should I do in case of OVERDOSE?
Call the poison control helpline at
Symptoms of overdose may include the following:
-
narrowing or widening of the pupils (black circles in the center of the eye)
-
slowed or difficulty breathing
-
extreme sleepiness or drowsiness
-
coma (loss of consciousness for a period of time)
-
slow heartbeat
What OTHER INFORMATION should I know?
Before having any laboratory test (especially those that involve methylene blue), tell your doctor and the laboratory personnel that you are using buprenorphine injection.
In the case of an emergency, a family member or caregiver should tell the emergency medical staff that you are physically dependent on an opioid and are receiving treatment with buprenorphine extended-release injection.
Buprenorphine extended-release injection is a controlled substance. Be sure to schedule appointments with your doctor on a regular basis to receive your injections. Ask your pharmacist if you have any questions.
It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.
Drug interactions
Drug | Interaction |
---|---|
Repaglinide | Repaglinide The metabolism of Buprenorphine can be decreased when combined with Repaglinide. |
Montelukast | Montelukast The metabolism of Buprenorphine can be decreased when combined with Montelukast. |
Leflunomide | Leflunomide Buprenorphine may decrease the excretion rate of Leflunomide which could result in a higher serum level. |
Delavirdine | Delavirdine The metabolism of Buprenorphine can be decreased when combined with Delavirdine. |
Nevirapine | Nevirapine The metabolism of Buprenorphine can be decreased when combined with Nevirapine. |
Atorvastatin | Atorvastatin The metabolism of Atorvastatin can be decreased when combined with Buprenorphine. |
Dolasetron | Dolasetron Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Aminophylline | Aminophylline The metabolism of Aminophylline can be decreased when combined with Buprenorphine. |
Bisacodyl | Bisacodyl The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Buprenorphine. |
Candesartan | Candesartan The metabolism of Buprenorphine can be decreased when combined with Candesartan. |
Cilostazol | Cilostazol The serum concentration of Cilostazol can be increased when it is combined with Buprenorphine. |
Clopidogrel | Clopidogrel Buprenorphine can cause a decrease in the absorption of Clopidogrel resulting in a reduced serum concentration and potentially a decrease in efficacy. |
Diphenoxylate | Diphenoxylate Diphenoxylate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Erythromycin and Sulfisoxazole | Erythromycin and Sulfisoxazole The metabolism of Buprenorphine can be decreased when combined with Erythromycin. |
Estrogen and Progestin (Oral Contraceptives) | Estrogen and Progestin (Oral Contraceptives) Buprenorphine may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level. |
Fenofibrate | Fenofibrate The metabolism of Buprenorphine can be decreased when combined with Fenofibrate. |
Guanfacine | Guanfacine Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Magnesium Hydroxide | Magnesium Hydroxide The therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Buprenorphine. |
Magnesium Oxide | Magnesium Oxide The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Buprenorphine. |
Naratriptan | Naratriptan Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Paregoric | Paregoric Morphine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Penbutolol | Penbutolol The metabolism of Buprenorphine can be decreased when combined with Acebutolol. |
Pentazocine | Pentazocine Pentazocine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Polyethylene glycol-electrolyte solution (PEG-ES) | Polyethylene glycol-electrolyte solution (PEG-ES) The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Buprenorphine. |
Potassium | Potassium The therapeutic efficacy of Potassium can be decreased when used in combination with Buprenorphine. |
Psyllium | Psyllium The therapeutic efficacy of Plantago seed can be decreased when used in combination with Buprenorphine. |
Ranitidine | Ranitidine The metabolism of Buprenorphine can be decreased when combined with Ranitidine. |
Reserpine | Reserpine Reserpine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Rizatriptan | Rizatriptan Rizatriptan may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Sumatriptan | Sumatriptan Sumatriptan may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Tacrolimus | Tacrolimus The serum concentration of Tacrolimus can be increased when it is combined with Buprenorphine. |
Tizanidine | Tizanidine Tizanidine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Triamcinolone | Triamcinolone The metabolism of Buprenorphine can be increased when combined with Triamcinolone. |
Zolmitriptan | Zolmitriptan Zolmitriptan may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Fluconazole Injection | Fluconazole Injection The metabolism of Buprenorphine can be decreased when combined with Fluconazole. |
Hydromorphone Injection | Hydromorphone Injection Hydromorphone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Meperidine Injection | Meperidine Injection Meperidine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Metoclopramide Injection | Metoclopramide Injection The therapeutic efficacy of Buprenorphine can be decreased when used in combination with Metoclopramide. |
Metronidazole Injection | Metronidazole Injection The metabolism of Buprenorphine can be decreased when combined with Metronidazole. |
Morphine Injection | Morphine Injection Morphine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Zidovudine Injection | Zidovudine Injection The metabolism of Buprenorphine can be increased when combined with Zidovudine. |
Altretamine | Altretamine The risk or severity of serotonin syndrome and opioid toxicity can be increased when Buprenorphine is combined with Amphetamine. |
Cyclosporine | Cyclosporine The metabolism of Cyclosporine can be decreased when combined with Buprenorphine. |
Ondansetron | Ondansetron Ondansetron may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Granisetron | Granisetron Granisetron may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Torsemide | Torsemide The metabolism of Buprenorphine can be decreased when combined with Torasemide. |
Olanzapine | Olanzapine Olanzapine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Alosetron | Alosetron Alosetron may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Dofetilide | Dofetilide The metabolism of Dofetilide can be decreased when combined with Buprenorphine. |
Entacapone | Entacapone Entacapone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Hydroxychloroquine | Hydroxychloroquine The metabolism of Buprenorphine can be decreased when combined with Hydroxychloroquine. |
Meloxicam | Meloxicam The metabolism of Buprenorphine can be decreased when combined with Meloxicam. |
Oxcarbazepine | Oxcarbazepine Oxcarbazepine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Pantoprazole | Pantoprazole The metabolism of Pantoprazole can be decreased when combined with Buprenorphine. |
Zaleplon | Zaleplon Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Anakinra | Anakinra The metabolism of Buprenorphine can be increased when combined with Anakinra. |
Desloratadine | Desloratadine Desloratadine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Linezolid | Linezolid The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Buprenorphine. |
Trimipramine | Trimipramine Trimipramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Etanercept Injection | Etanercept Injection The metabolism of Buprenorphine can be increased when combined with Etanercept. |
Glycopyrrolate | Glycopyrrolate The risk or severity of adverse effects can be increased when Buprenorphine is combined with Glycopyrronium. |
Modafinil | Modafinil The metabolism of Buprenorphine can be increased when combined with Modafinil. |
Tenofovir | Tenofovir The metabolism of Tenofovir can be decreased when combined with Buprenorphine. |
Sirolimus | Sirolimus The metabolism of Sirolimus can be decreased when combined with Buprenorphine. |
Dutasteride | Dutasteride The metabolism of Dutasteride can be decreased when combined with Buprenorphine. |
Epinephrine Injection | Epinephrine Injection The metabolism of Buprenorphine can be decreased when combined with Epinephrine. |
Eplerenone | Eplerenone The therapeutic efficacy of Buprenorphine can be decreased when used in combination with Eplerenone. |
Escitalopram | Escitalopram Escitalopram may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Zonisamide | Zonisamide Zonisamide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Adalimumab Injection | Adalimumab Injection The metabolism of Buprenorphine can be increased when combined with Adalimumab. |
Aripiprazole | Aripiprazole Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Atomoxetine | Atomoxetine Atomoxetine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Dexmethylphenidate | Dexmethylphenidate Dexmethylphenidate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Ezetimibe | Ezetimibe Buprenorphine may decrease the excretion rate of Ezetimibe which could result in a higher serum level. |
Atazanavir | Atazanavir The metabolism of Atazanavir can be decreased when combined with Buprenorphine. |
Almotriptan | Almotriptan Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Eletriptan | Eletriptan Eletriptan may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Mefloquine | Mefloquine The metabolism of Buprenorphine can be decreased when combined with Mefloquine. |
Polyethylene Glycol 3350 | Polyethylene Glycol 3350 The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Buprenorphine. |
Rosuvastatin | Rosuvastatin Buprenorphine may decrease the excretion rate of Rosuvastatin which could result in a higher serum level. |
Vardenafil | Vardenafil The metabolism of Vardenafil can be decreased when combined with Buprenorphine. |
Alfuzosin | Alfuzosin The metabolism of Alfuzosin can be decreased when combined with Buprenorphine. |
Aprepitant | Aprepitant The metabolism of Buprenorphine can be decreased when combined with Aprepitant. |
Tegaserod | Tegaserod The metabolism of Buprenorphine can be decreased when combined with Tegaserod. |
Tadalafil | Tadalafil The metabolism of Buprenorphine can be decreased when combined with Tadalafil. |
Frovatriptan | Frovatriptan Frovatriptan may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Progesterone | Progesterone The metabolism of Buprenorphine can be decreased when combined with Progesterone. |
Apomorphine Injection | Apomorphine Injection Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Infliximab Injection | Infliximab Injection The metabolism of Buprenorphine can be increased when combined with Infliximab. |
Oxandrolone | Oxandrolone The metabolism of Buprenorphine can be decreased when combined with Oxandrolone. |
Protriptyline | Protriptyline Protriptyline may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Rifaximin | Rifaximin The metabolism of Buprenorphine can be increased when combined with Rifaximin. |
Duloxetine | Duloxetine Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Norethindrone | Norethindrone The metabolism of Buprenorphine can be decreased when combined with Norethisterone. |
Trospium | Trospium The risk or severity of adverse effects can be increased when Buprenorphine is combined with Trospium. |
Bosentan | Bosentan The metabolism of Buprenorphine can be increased when combined with Bosentan. |
Cinacalcet | Cinacalcet The metabolism of Buprenorphine can be decreased when combined with Cinacalcet. |
Erlotinib | Erlotinib The metabolism of Buprenorphine can be decreased when combined with Erlotinib. |
Eszopiclone | Eszopiclone Eszopiclone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Solifenacin | Solifenacin The risk or severity of adverse effects can be increased when Buprenorphine is combined with Solifenacin. |
Voriconazole | Voriconazole The metabolism of Buprenorphine can be decreased when combined with Voriconazole. |
Dextroamphetamine | Dextroamphetamine The risk or severity of serotonin syndrome and opioid toxicity can be increased when Buprenorphine is combined with Amphetamine. |
Peginterferon Alfa-2b (PEG-Intron) | Peginterferon Alfa-2b (PEG-Intron) The metabolism of Buprenorphine can be increased when combined with Peginterferon alfa-2b. |
Sodium Oxybate | Sodium Oxybate Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Isocarboxazid | Isocarboxazid The risk or severity of serotonin syndrome and opioid toxicity can be increased when Buprenorphine is combined with Isocarboxazid. |
Ramelteon | Ramelteon Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Darifenacin | Darifenacin The metabolism of Darifenacin can be decreased when combined with Buprenorphine. |
Fentanyl | Fentanyl The metabolism of Fentanyl can be decreased when combined with Buprenorphine. |
Pregabalin | Pregabalin Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Deferasirox | Deferasirox The metabolism of Buprenorphine can be decreased when combined with Deferasirox. |
Tipranavir | Tipranavir The metabolism of Tipranavir can be decreased when combined with Buprenorphine. |
Felbamate | Felbamate Felbamate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Ranolazine | Ranolazine The serum concentration of Ranolazine can be increased when it is combined with Buprenorphine. |
Abatacept Injection | Abatacept Injection The metabolism of Buprenorphine can be increased when combined with Abatacept. |
Rasagiline | Rasagiline The risk or severity of serotonin syndrome and opioid toxicity can be increased when Buprenorphine is combined with Rasagiline. |
Imatinib | Imatinib The metabolism of Buprenorphine can be decreased when combined with Imatinib. |
Sitagliptin | Sitagliptin The metabolism of Sitagliptin can be decreased when combined with Buprenorphine. |
Gefitinib | Gefitinib Buprenorphine may decrease the excretion rate of Gefitinib which could result in a higher serum level. |
Paliperidone | Paliperidone Paliperidone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Bortezomib | Bortezomib The metabolism of Buprenorphine can be decreased when combined with Bortezomib. |
Clofarabine Injection | Clofarabine Injection Buprenorphine may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
Lubiprostone | Lubiprostone The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Buprenorphine. |
Oxaliplatin Injection | Oxaliplatin Injection Buprenorphine may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. |
Primaquine | Primaquine The metabolism of Buprenorphine can be decreased when combined with Primaquine. |
Darunavir | Darunavir The serum concentration of Darunavir can be increased when it is combined with Buprenorphine. |
Dimenhydrinate | Dimenhydrinate Dimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Lisdexamfetamine | Lisdexamfetamine Lisdexamfetamine may increase the analgesic activities of Buprenorphine. |
Nabilone | Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Retapamulin | Retapamulin The metabolism of Retapamulin can be decreased when combined with Buprenorphine. |
Sorafenib | Sorafenib The metabolism of Buprenorphine can be decreased when combined with Sorafenib. |
Sunitinib | Sunitinib The metabolism of Sunitinib can be decreased when combined with Buprenorphine. |
Dronabinol | Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Lapatinib | Lapatinib The metabolism of Buprenorphine can be decreased when combined with Lapatinib. |
Levocetirizine | Levocetirizine Levocetirizine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Dasatinib | Dasatinib The metabolism of Dasatinib can be decreased when combined with Buprenorphine. |
Mexiletine | Mexiletine The metabolism of Mexiletine can be decreased when combined with Buprenorphine. |
Armodafinil | Armodafinil The metabolism of Buprenorphine can be increased when combined with Armodafinil. |
Ivermectin | Ivermectin Buprenorphine may decrease the excretion rate of Ivermectin which could result in a higher serum level. |
Paclitaxel (with polyoxyethylated castor oil) Injection | Paclitaxel (with polyoxyethylated castor oil) Injection The therapeutic efficacy of Castor oil can be decreased when used in combination with Buprenorphine. |
Temsirolimus | Temsirolimus The metabolism of Temsirolimus can be decreased when combined with Buprenorphine. |
Nilotinib | Nilotinib The metabolism of Buprenorphine can be decreased when combined with Nilotinib. |
Bexarotene | Bexarotene The metabolism of Buprenorphine can be decreased when combined with Bexarotene. |
Budesonide | Budesonide The metabolism of Buprenorphine can be increased when combined with Budesonide. |
Chloramphenicol Injection | Chloramphenicol Injection The metabolism of Buprenorphine can be decreased when combined with Chloramphenicol. |
Desmopressin | Desmopressin The risk or severity of hyponatremia can be increased when Buprenorphine is combined with Desmopressin. |
OnabotulinumtoxinA Injection | OnabotulinumtoxinA Injection Botulinum toxin type A may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
RimabotulinumtoxinB Injection | RimabotulinumtoxinB Injection Botulinum Toxin Type B may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Etravirine | Etravirine The metabolism of Etravirine can be decreased when combined with Buprenorphine. |
Mitoxantrone Injection | Mitoxantrone Injection Buprenorphine may decrease the excretion rate of Mitoxantrone which could result in a higher serum level. |
Desvenlafaxine | Desvenlafaxine Desvenlafaxine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Cevimeline | Cevimeline The metabolism of Cevimeline can be decreased when combined with Buprenorphine. |
Nebivolol | Nebivolol The metabolism of Nebivolol can be decreased when combined with Buprenorphine. |
Tretinoin | Tretinoin The metabolism of Buprenorphine can be decreased when combined with Tretinoin. |
Flecainide | Flecainide The metabolism of Flecainide can be decreased when combined with Buprenorphine. |
Certolizumab Injection | Certolizumab Injection The metabolism of Buprenorphine can be increased when combined with Certolizumab pegol. |
Ixabepilone Injection | Ixabepilone Injection The metabolism of Ixabepilone can be decreased when combined with Buprenorphine. |
Irinotecan Injection | Irinotecan Injection The metabolism of Irinotecan can be decreased when combined with Buprenorphine. |
Praziquantel | Praziquantel The metabolism of Praziquantel can be decreased when combined with Buprenorphine. |
Alvimopan | Alvimopan The risk or severity of adverse effects can be increased when Buprenorphine is combined with Alvimopan. |
Methylnaltrexone Injection | Methylnaltrexone Injection Buprenorphine may increase the opioid antagonism activities of Methylnaltrexone. |
Rufinamide | Rufinamide Rufinamide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Midazolam | Midazolam The serum concentration of Midazolam can be increased when it is combined with Buprenorphine. |
Naltrexone Injection | Naltrexone Injection The therapeutic efficacy of Buprenorphine can be decreased when used in combination with Naltrexone. |
Eltrombopag | Eltrombopag The metabolism of Buprenorphine can be decreased when combined with Eltrombopag. |
Milnacipran | Milnacipran Milnacipran may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Dexlansoprazole | Dexlansoprazole The metabolism of Dexlansoprazole can be decreased when combined with Buprenorphine. |
Sodium Phosphate | Sodium Phosphate The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Buprenorphine. |
Fesoterodine | Fesoterodine The risk or severity of adverse effects can be increased when Buprenorphine is combined with Fesoterodine. |
Betaxolol | Betaxolol The metabolism of Betaxolol can be decreased when combined with Buprenorphine. |
Iloperidone | Iloperidone Iloperidone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Prasugrel | Prasugrel The metabolism of Prasugrel can be decreased when combined with Buprenorphine. |
Lacosamide | Lacosamide Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Everolimus | Everolimus The metabolism of Everolimus can be decreased when combined with Buprenorphine. |
Tolvaptan (low blood sodium) | Tolvaptan (low blood sodium) The metabolism of Tolvaptan can be decreased when combined with Buprenorphine. |
Dronedarone | Dronedarone The metabolism of Dronedarone can be decreased when combined with Buprenorphine. |
AbobotulinumtoxinA Injection | AbobotulinumtoxinA Injection Botulinum toxin type A may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Pralatrexate Injection | Pralatrexate Injection Buprenorphine may decrease the excretion rate of Pralatrexate which could result in a higher serum level. |
Palonosetron Injection | Palonosetron Injection Palonosetron may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Saxagliptin | Saxagliptin The metabolism of Saxagliptin can be decreased when combined with Buprenorphine. |
Romidepsin Injection | Romidepsin Injection The metabolism of Romidepsin can be decreased when combined with Buprenorphine. |
Tapentadol | Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Topotecan | Topotecan Buprenorphine may decrease the excretion rate of Topotecan which could result in a higher serum level. |
Golimumab Injection | Golimumab Injection The metabolism of Buprenorphine can be increased when combined with Golimumab. |
Pazopanib | Pazopanib The metabolism of Pazopanib can be decreased when combined with Buprenorphine. |
Asenapine | Asenapine Asenapine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Vigabatrin | Vigabatrin Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Pitavastatin | Pitavastatin Buprenorphine may decrease the excretion rate of Pitavastatin which could result in a higher serum level. |
Albendazole | Albendazole The metabolism of Albendazole can be decreased when combined with Buprenorphine. |
Levonorgestrel | Levonorgestrel The metabolism of Buprenorphine can be decreased when combined with Levonorgestrel. |
Oxymorphone | Oxymorphone Oxymorphone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Tocilizumab Injection | Tocilizumab Injection The metabolism of Buprenorphine can be increased when combined with Tocilizumab. |
IncobotulinumtoxinA Injection | IncobotulinumtoxinA Injection Botulinum toxin type A may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Cabazitaxel Injection | Cabazitaxel Injection The metabolism of Cabazitaxel can be decreased when combined with Buprenorphine. |
Lurasidone | Lurasidone Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Acetaminophen Injection | Acetaminophen Injection The metabolism of Acetaminophen can be decreased when combined with Buprenorphine. |
Vilazodone | Vilazodone Vilazodone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Busulfan Injection | Busulfan Injection The metabolism of Busulfan can be decreased when combined with Buprenorphine. |
Roflumilast | Roflumilast The metabolism of Roflumilast can be decreased when combined with Buprenorphine. |
Linagliptin | Linagliptin The metabolism of Linagliptin can be decreased when combined with Buprenorphine. |
Rilpivirine | Rilpivirine The metabolism of Buprenorphine can be decreased when combined with Rilpivirine. |
Telaprevir | Telaprevir The metabolism of Buprenorphine can be decreased when combined with Glecaprevir. |
Cyclophosphamide Injection | Cyclophosphamide Injection The metabolism of Cyclophosphamide can be decreased when combined with Buprenorphine. |
Abiraterone | Abiraterone The metabolism of Buprenorphine can be decreased when combined with Abiraterone. |
Rivaroxaban | Rivaroxaban Buprenorphine may decrease the excretion rate of Rivaroxaban which could result in a higher serum level. |
Ticagrelor | Ticagrelor Ticagrelor can cause a decrease in the absorption of Buprenorphine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
Brentuximab Vedotin Injection | Brentuximab Vedotin Injection The metabolism of Brentuximab vedotin can be decreased when combined with Buprenorphine. |
Ruxolitinib | Ruxolitinib The metabolism of Ruxolitinib can be decreased when combined with Buprenorphine. |
Vandetanib | Vandetanib The metabolism of Vandetanib can be decreased when combined with Buprenorphine. |
Clobazam | Clobazam Clobazam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Vemurafenib | Vemurafenib The metabolism of Vemurafenib can be decreased when combined with Buprenorphine. |
Vismodegib | Vismodegib The metabolism of Buprenorphine can be decreased when combined with Vismodegib. |
Ivacaftor | Ivacaftor The metabolism of Ivacaftor can be decreased when combined with Buprenorphine. |
Axitinib | Axitinib The metabolism of Axitinib can be decreased when combined with Buprenorphine. |
Crizotinib | Crizotinib The metabolism of Buprenorphine can be decreased when combined with Crizotinib. |
Cabergoline | Cabergoline Cabergoline may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Ambrisentan | Ambrisentan The metabolism of Ambrisentan can be decreased when combined with Buprenorphine. |
Ezogabine | Ezogabine Tiagabine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Enzalutamide | Enzalutamide The metabolism of Enzalutamide can be increased when combined with Buprenorphine. |
Mirabegron | Mirabegron The metabolism of Mirabegron can be decreased when combined with Buprenorphine. |
Regorafenib | Regorafenib The metabolism of Buprenorphine can be decreased when combined with Regorafenib. |
Bosutinib | Bosutinib The metabolism of Buprenorphine can be decreased when combined with Bosutinib. |
Linaclotide | Linaclotide The therapeutic efficacy of Linaclotide can be decreased when used in combination with Buprenorphine. |
Teriflunomide | Teriflunomide Buprenorphine may decrease the excretion rate of Teriflunomide which could result in a higher serum level. |
Cabozantinib (thyroid cancer) | Cabozantinib (thyroid cancer) The metabolism of Cabozantinib can be decreased when combined with Buprenorphine. |
Tofacitinib | Tofacitinib The metabolism of Tofacitinib can be decreased when combined with Buprenorphine. |
Alogliptin | Alogliptin The metabolism of Alogliptin can be decreased when combined with Buprenorphine. |
Ponatinib | Ponatinib The metabolism of Ponatinib can be decreased when combined with Buprenorphine. |
Pomalidomide | Pomalidomide Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Ado-trastuzumab Emtansine Injection | Ado-trastuzumab Emtansine Injection The metabolism of Trastuzumab emtansine can be decreased when combined with Buprenorphine. |
Apixaban | Apixaban Buprenorphine may decrease the excretion rate of Apixaban which could result in a higher serum level. |
Canagliflozin | Canagliflozin The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Buprenorphine. |
Methazolamide | Methazolamide The therapeutic efficacy of Methazolamide can be decreased when used in combination with Buprenorphine. |
Dabrafenib | Dabrafenib The metabolism of Buprenorphine can be decreased when combined with Dabrafenib. |
Ospemifene | Ospemifene The metabolism of Ospemifene can be decreased when combined with Buprenorphine. |
Trametinib | Trametinib The metabolism of Buprenorphine can be decreased when combined with Trametinib. |
Dolutegravir | Dolutegravir Buprenorphine may decrease the excretion rate of Dolutegravir which could result in a higher serum level. |
Afatinib | Afatinib Buprenorphine may decrease the excretion rate of Afatinib which could result in a higher serum level. |
Levomilnacipran | Levomilnacipran Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Vortioxetine | Vortioxetine Vortioxetine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Perampanel | Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Ibrutinib | Ibrutinib The metabolism of Ibrutinib can be decreased when combined with Buprenorphine. |
Lomitapide | Lomitapide The metabolism of Lomitapide can be decreased when combined with Buprenorphine. |
Ketorolac Injection | Ketorolac Injection The metabolism of Buprenorphine can be decreased when combined with Ketorolac. |
Simeprevir | Simeprevir Buprenorphine may decrease the excretion rate of Simeprevir which could result in a higher serum level. |
Sofosbuvir | Sofosbuvir Buprenorphine may decrease the excretion rate of Sofosbuvir which could result in a higher serum level. |
Dapagliflozin | Dapagliflozin The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Buprenorphine. |
Apremilast | Apremilast The metabolism of Buprenorphine can be increased when combined with Apremilast. |
Ceritinib | Ceritinib The metabolism of Ceritinib can be decreased when combined with Buprenorphine. |
Siltuximab Injection | Siltuximab Injection The metabolism of Buprenorphine can be increased when combined with Siltuximab. |
Eslicarbazepine | Eslicarbazepine Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Idelalisib | Idelalisib The metabolism of Idelalisib can be decreased when combined with Buprenorphine. |
Testosterone Injection | Testosterone Injection Buprenorphine may decrease the excretion rate of Testosterone which could result in a higher serum level. |
Oritavancin Injection | Oritavancin Injection The metabolism of Buprenorphine can be decreased when combined with Oritavancin. |
Vorapaxar | Vorapaxar The metabolism of Vorapaxar can be decreased when combined with Buprenorphine. |
Hydrocodone | Hydrocodone The therapeutic efficacy of Hydrocodone can be decreased when used in combination with Buprenorphine. |
Suvorexant | Suvorexant Buprenorphine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
Olaparib | Olaparib The metabolism of Olaparib can be decreased when combined with Buprenorphine. |
Methamphetamine | Methamphetamine Metamfetamine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Tasimelteon | Tasimelteon Tasimelteon may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Riociguat | Riociguat Buprenorphine may decrease the excretion rate of Riociguat which could result in a higher serum level. |
Nintedanib | Nintedanib The metabolism of Nintedanib can be decreased when combined with Buprenorphine. |
Secukinumab Injection | Secukinumab Injection The metabolism of Buprenorphine can be increased when combined with Secukinumab. |
Risperidone Injection | Risperidone Injection Risperidone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Palbociclib | Palbociclib The metabolism of Palbociclib can be decreased when combined with Buprenorphine. |
Lenvatinib | Lenvatinib Buprenorphine may decrease the excretion rate of Lenvatinib which could result in a higher serum level. |
Naloxegol | Naloxegol Buprenorphine may increase the opioid antagonism activities of Naloxegol. |
Panobinostat | Panobinostat The metabolism of Panobinostat can be decreased when combined with Buprenorphine. |
Haloperidol Injection | Haloperidol Injection Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Amiloride | Amiloride The therapeutic efficacy of Amiloride can be decreased when used in combination with Buprenorphine. |
Sonidegib | Sonidegib The metabolism of Sonidegib can be decreased when combined with Buprenorphine. |
Flibanserin | Flibanserin Flibanserin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Rolapitant | Rolapitant The metabolism of Buprenorphine can be decreased when combined with Rolapitant. |
Daclatasvir | Daclatasvir The metabolism of Daclatasvir can be decreased when combined with Buprenorphine. |
Brexpiprazole | Brexpiprazole Brexpiprazole may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Ziprasidone Injection | Ziprasidone Injection Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Cariprazine | Cariprazine Cariprazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Eluxadoline | Eluxadoline The risk or severity of constipation can be increased when Buprenorphine is combined with Eluxadoline. |
Cobimetinib | Cobimetinib The metabolism of Cobimetinib can be decreased when combined with Buprenorphine. |
Trabectedin Injection | Trabectedin Injection The metabolism of Trabectedin can be decreased when combined with Buprenorphine. |
Osimertinib | Osimertinib The metabolism of Osimertinib can be decreased when combined with Buprenorphine. |
Alectinib | Alectinib The metabolism of Alectinib can be decreased when combined with Buprenorphine. |
Ixazomib | Ixazomib The metabolism of Ixazomib can be decreased when combined with Buprenorphine. |
Rifapentine | Rifapentine The metabolism of Buprenorphine can be increased when combined with Rifapentine. |
Lesinurad | Lesinurad The metabolism of Lesinurad can be decreased when combined with Buprenorphine. |
Dexamethasone Injection | Dexamethasone Injection The metabolism of Buprenorphine can be increased when combined with Dexamethasone. |
Brivaracetam Injection | Brivaracetam Injection Brivaracetam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Venetoclax | Venetoclax The metabolism of Venetoclax can be decreased when combined with Buprenorphine. |
Cobicistat | Cobicistat The serum concentration of Buprenorphine can be increased when it is combined with Cobicistat. |
Selexipag | Selexipag The metabolism of Selexipag can be decreased when combined with Buprenorphine. |
Pimavanserin | Pimavanserin Pimavanserin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Diphenhydramine Injection | Diphenhydramine Injection Diphenhydramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Furosemide Injection | Furosemide Injection The therapeutic efficacy of Furosemide can be decreased when used in combination with Buprenorphine. |
Rucaparib | Rucaparib The metabolism of Buprenorphine can be decreased when combined with Rucaparib. |
Ribociclib | Ribociclib The metabolism of Ribociclib can be decreased when combined with Buprenorphine. |
Brigatinib | Brigatinib The metabolism of Brigatinib can be decreased when combined with Buprenorphine. |
Doxepin (Insomnia) | Doxepin (Insomnia) Doxepin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Plecanatide | Plecanatide The therapeutic efficacy of Plecanatide can be decreased when used in combination with Buprenorphine. |
Deutetrabenazine | Deutetrabenazine The metabolism of Deutetrabenazine can be decreased when combined with Buprenorphine. |
Valbenazine | Valbenazine The metabolism of Valbenazine can be decreased when combined with Buprenorphine. |
Deflazacort | Deflazacort The metabolism of Buprenorphine can be increased when combined with Deflazacort. |
Safinamide | Safinamide The risk or severity of serotonin syndrome and opioid toxicity can be increased when Buprenorphine is combined with Safinamide. |
Naldemedine | Naldemedine The therapeutic efficacy of Buprenorphine can be decreased when used in combination with Naldemedine. |
Midostaurin | Midostaurin The metabolism of Buprenorphine can be decreased when combined with Midostaurin. |
Neratinib | Neratinib The metabolism of Neratinib can be decreased when combined with Buprenorphine. |
Enasidenib | Enasidenib The metabolism of Buprenorphine can be decreased when combined with Enasidenib. |
Aprepitant/Fosaprepitant Injection | Aprepitant/Fosaprepitant Injection The metabolism of Fosaprepitant can be decreased when combined with Buprenorphine. |
Copanlisib Injection | Copanlisib Injection The metabolism of Copanlisib can be decreased when combined with Buprenorphine. |
Delafloxacin | Delafloxacin Buprenorphine may decrease the excretion rate of Delafloxacin which could result in a higher serum level. |
Abemaciclib | Abemaciclib The metabolism of Abemaciclib can be decreased when combined with Buprenorphine. |
Acalabrutinib | Acalabrutinib The metabolism of Buprenorphine can be decreased when combined with Acalabrutinib. |
Letermovir | Letermovir The metabolism of Buprenorphine can be decreased when combined with Letermovir. |
Tetrabenazine | Tetrabenazine The metabolism of Tetrabenazine can be decreased when combined with Buprenorphine. |
Ertugliflozin | Ertugliflozin The metabolism of Buprenorphine can be decreased when combined with Ertugliflozin. |
Apalutamide | Apalutamide The metabolism of Buprenorphine can be decreased when combined with Apalutamide. |
Fostamatinib | Fostamatinib The metabolism of Buprenorphine can be decreased when combined with Fostamatinib. |
Avatrombopag | Avatrombopag The metabolism of Buprenorphine can be increased when combined with Avatrombopag. |
Baricitinib | Baricitinib The metabolism of Baricitinib can be decreased when combined with Buprenorphine. |
Lofexidine | Lofexidine The therapeutic efficacy of Buprenorphine can be increased when used in combination with Lofexidine. |
Eliglustat | Eliglustat The metabolism of Eliglustat can be decreased when combined with Buprenorphine. |
Encorafenib | Encorafenib The metabolism of Encorafenib can be decreased when combined with Buprenorphine. |
Ivosidenib | Ivosidenib The metabolism of Ivosidenib can be decreased when combined with Buprenorphine. |
Lusutrombopag | Lusutrombopag Buprenorphine may decrease the excretion rate of Lusutrombopag which could result in a higher serum level. |
Elagolix | Elagolix The metabolism of Elagolix can be decreased when combined with Buprenorphine. |
Doravirine | Doravirine The metabolism of Doravirine can be decreased when combined with Buprenorphine. |
Tafenoquine | Tafenoquine The metabolism of Tafenoquine can be decreased when combined with Buprenorphine. |
Cannabidiol | Cannabidiol Cannabidiol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Dacomitinib | Dacomitinib The metabolism of Buprenorphine can be decreased when combined with Dacomitinib. |
Duvelisib | Duvelisib Buprenorphine may decrease the excretion rate of Duvelisib which could result in a higher serum level. |
Stiripentol | Stiripentol Stiripentol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Talazoparib | Talazoparib Buprenorphine may decrease the excretion rate of Talazoparib which could result in a higher serum level. |
Gilteritinib | Gilteritinib The metabolism of Gilteritinib can be decreased when combined with Buprenorphine. |
Glasdegib | Glasdegib Buprenorphine may decrease the excretion rate of Glasdegib which could result in a higher serum level. |
Lorlatinib | Lorlatinib The metabolism of Lorlatinib can be decreased when combined with Buprenorphine. |
Paclitaxel (with albumin) Injection | Paclitaxel (with albumin) Injection The metabolism of Paclitaxel can be decreased when combined with Buprenorphine. |
Rifamycin | Rifamycin The metabolism of Buprenorphine can be decreased when combined with Rifamycin. |
Prucalopride | Prucalopride The metabolism of Prucalopride can be decreased when combined with Buprenorphine. |
Magnesium Citrate | Magnesium Citrate The therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Buprenorphine. |
Emapalumab-lzsg Injection | Emapalumab-lzsg Injection The metabolism of Buprenorphine can be increased when combined with Emapalumab. |
Siponimod | Siponimod The metabolism of Siponimod can be decreased when combined with Buprenorphine. |
Erdafitinib | Erdafitinib The metabolism of Erdafitinib can be decreased when combined with Buprenorphine. |
Esomeprazole Injection | Esomeprazole Injection The metabolism of Esomeprazole can be decreased when combined with Buprenorphine. |
Alpelisib | Alpelisib The serum concentration of Alpelisib can be increased when it is combined with Buprenorphine. |
Brexanolone Injection | Brexanolone Injection Brexanolone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Cladribine | Cladribine Buprenorphine may decrease the excretion rate of Cladribine which could result in a higher serum level. |
Solriamfetol | Solriamfetol Solriamfetol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Darolutamide | Darolutamide Buprenorphine may decrease the excretion rate of Darolutamide which could result in a higher serum level. |
Triclabendazole | Triclabendazole The metabolism of Buprenorphine can be decreased when combined with Triclabendazole. |
Entrectinib | Entrectinib The metabolism of Entrectinib can be decreased when combined with Buprenorphine. |
Pexidartinib | Pexidartinib The metabolism of Buprenorphine can be decreased when combined with Pexidartinib. |
Istradefylline | Istradefylline The metabolism of Istradefylline can be decreased when combined with Buprenorphine. |
Pitolisant | Pitolisant The serum concentration of Buprenorphine can be decreased when it is combined with Pitolisant. |
Fedratinib | Fedratinib The metabolism of Fedratinib can be decreased when combined with Buprenorphine. |
Lefamulin | Lefamulin The metabolism of Lefamulin can be decreased when combined with Buprenorphine. |
Phenytoin Injection | Phenytoin Injection Phenytoin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Fosphenytoin Injection | Fosphenytoin Injection Fosphenytoin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Zanubrutinib | Zanubrutinib The metabolism of Zanubrutinib can be decreased when combined with Buprenorphine. |
Voxelotor | Voxelotor The serum concentration of Voxelotor can be increased when it is combined with Buprenorphine. |
Avapritinib | Avapritinib The metabolism of Avapritinib can be decreased when combined with Buprenorphine. |
Lumateperone | Lumateperone Lumateperone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Lasmiditan | Lasmiditan Lasmiditan may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Ubrogepant | Ubrogepant The serum concentration of Ubrogepant can be increased when it is combined with Buprenorphine. |
Tazemetostat | Tazemetostat Buprenorphine may decrease the excretion rate of Tazemetostat which could result in a higher serum level. |
Cenobamate | Cenobamate The serum concentration of Buprenorphine can be decreased when it is combined with Cenobamate. |
Ozanimod | Ozanimod Buprenorphine may decrease the excretion rate of Ozanimod which could result in a higher serum level. |
Selumetinib | Selumetinib Buprenorphine may decrease the excretion rate of Selumetinib which could result in a higher serum level. |
Rimegepant | Rimegepant The serum concentration of Rimegepant can be increased when it is combined with Buprenorphine. |
Tucatinib | Tucatinib The metabolism of Tucatinib can be decreased when combined with Buprenorphine. |
Ripretinib | Ripretinib Buprenorphine may decrease the excretion rate of Ripretinib which could result in a higher serum level. |
Selpercatinib | Selpercatinib The serum concentration of Buprenorphine can be increased when it is combined with Selpercatinib. |
Lemborexant | Lemborexant Buprenorphine may increase the central nervous system depressant (CNS depressant) activities of Lemborexant. |
Fenfluramine | Fenfluramine Fenfluramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Pralsetinib | Pralsetinib Buprenorphine may decrease the excretion rate of Pralsetinib which could result in a higher serum level. |
Opicapone | Opicapone The metabolism of Buprenorphine can be decreased when combined with Opicapone. |
Satralizumab-mwge Injection | Satralizumab-mwge Injection The serum concentration of Buprenorphine can be decreased when it is combined with Satralizumab. |
Progestin-Only (drospirenone) Oral Contraceptives | Progestin-Only (drospirenone) Oral Contraceptives The therapeutic efficacy of Drospirenone can be decreased when used in combination with Buprenorphine. |
Viloxazine | Viloxazine Viloxazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Theophylline | Theophylline The metabolism of Theophylline can be decreased when combined with Buprenorphine. |
Indomethacin | Indomethacin The metabolism of Buprenorphine can be decreased when combined with Indomethacin. |
Mefenamic Acid | Mefenamic Acid The metabolism of Buprenorphine can be decreased when combined with Mefenamic acid. |
Naproxen | Naproxen The metabolism of Buprenorphine can be decreased when combined with Naproxen. |
Trazodone | Trazodone Trazodone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Hydroxyurea | Hydroxyurea The metabolism of Buprenorphine can be decreased when combined with Hydroxyurea. |
Floxuridine | Floxuridine The metabolism of Buprenorphine can be decreased when combined with Floxuridine. |
Phenobarbital | Phenobarbital Phenobarbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Metaxalone | Metaxalone Metaxalone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Methotrexate Injection | Methotrexate Injection The metabolism of Methotrexate can be decreased when combined with Buprenorphine. |
Levorphanol | Levorphanol Levorphanol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Primidone | Primidone Primidone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Methsuximide | Methsuximide Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Diethylpropion | Diethylpropion Diethylpropion may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Chlorpromazine | Chlorpromazine Chlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Diazepam | Diazepam Diazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Oxazepam | Oxazepam Oxazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Flurazepam | Flurazepam Flurazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Clorazepate | Clorazepate Clorazepic acid may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Lorazepam | Lorazepam Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Amantadine | Amantadine The risk or severity of adverse effects can be increased when Amantadine is combined with Buprenorphine. |
Codeine | Codeine Codeine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Meprobamate | Meprobamate Meprobamate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Chlordiazepoxide | Chlordiazepoxide Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Bromocriptine | Bromocriptine Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Tranylcypromine | Tranylcypromine The risk or severity of serotonin syndrome and opioid toxicity can be increased when Buprenorphine is combined with Tranylcypromine. |
Phenelzine | Phenelzine The risk or severity of serotonin syndrome and opioid toxicity can be increased when Buprenorphine is combined with Phenelzine. |
Procarbazine | Procarbazine The risk or severity of serotonin syndrome and opioid toxicity can be increased when Buprenorphine is combined with Procarbazine. |
Ergoloid Mesylates | Ergoloid Mesylates Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Minocycline | Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Prochlorperazine | Prochlorperazine Prochlorperazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Thioridazine | Thioridazine Thioridazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Trifluoperazine | Trifluoperazine Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Dapsone | Dapsone The metabolism of Dapsone can be decreased when combined with Buprenorphine. |
Sulfadiazine | Sulfadiazine The metabolism of Buprenorphine can be decreased when combined with Sulfadiazine. |
Oxycodone | Oxycodone Oxycodone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Methadone | Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Buprenorphine. |
Oxybutynin | Oxybutynin The risk or severity of adverse effects can be increased when Oxybutynin is combined with Buprenorphine. |
Benztropine | Benztropine The risk or severity of adverse effects can be increased when Buprenorphine is combined with Benzatropine. |
Maprotiline | Maprotiline Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Ibuprofen | Ibuprofen The metabolism of Ibuprofen can be decreased when combined with Buprenorphine. |
Trihexyphenidyl | Trihexyphenidyl The risk or severity of adverse effects can be increased when Buprenorphine is combined with Trihexyphenidyl. |
Orphenadrine | Orphenadrine Orphenadrine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Perphenazine | Perphenazine Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Fluphenazine | Fluphenazine Fluphenazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Phentermine | Phentermine Phentermine may increase the analgesic activities of Buprenorphine. |
Amoxapine | Amoxapine Amoxapine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Sulfasalazine | Sulfasalazine Buprenorphine may decrease the excretion rate of Sulfasalazine which could result in a higher serum level. |
Hydrocortisone | Hydrocortisone The metabolism of Buprenorphine can be increased when combined with Hydrocortisone. |
Doxorubicin | Doxorubicin The metabolism of Doxorubicin can be decreased when combined with Buprenorphine. |
Dactinomycin | Dactinomycin Buprenorphine may decrease the excretion rate of Dactinomycin which could result in a higher serum level. |
Carbamazepine | Carbamazepine Carbamazepine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Molindone | Molindone Molindone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Clonidine | Clonidine The risk or severity of sedation can be increased when Clonidine is combined with Buprenorphine. |
Prazosin | Prazosin Buprenorphine may decrease the excretion rate of Prazosin which could result in a higher serum level. |
Cimetidine | Cimetidine The metabolism of Cimetidine can be decreased when combined with Buprenorphine. |
Warfarin | Warfarin The serum concentration of Warfarin can be increased when it is combined with Buprenorphine. |
Clonazepam | Clonazepam Clonazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Loperamide | Loperamide The metabolism of Buprenorphine can be decreased when combined with Loperamide. |
Promethazine | Promethazine Promethazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Daunorubicin | Daunorubicin Buprenorphine may decrease the excretion rate of Daunorubicin which could result in a higher serum level. |
Nitrofurantoin | Nitrofurantoin Buprenorphine may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level. |
Griseofulvin | Griseofulvin The metabolism of Buprenorphine can be increased when combined with Griseofulvin. |
Loxapine | Loxapine Loxapine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Chloroquine | Chloroquine The metabolism of Buprenorphine can be decreased when combined with Chloroquine. |
Quinine | Quinine Quinine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Ethosuximide | Ethosuximide Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Triamterene | Triamterene The therapeutic efficacy of Triamterene can be decreased when used in combination with Buprenorphine. |
Lactulose | Lactulose The therapeutic efficacy of Lactulose can be decreased when used in combination with Buprenorphine. |
Sulfinpyrazone | Sulfinpyrazone The metabolism of Buprenorphine can be decreased when combined with Sulfinpyrazone. |
Chlorothiazide | Chlorothiazide The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Buprenorphine. |
Chlorthalidone | Chlorthalidone The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Buprenorphine. |
Metolazone | Metolazone The therapeutic efficacy of Metolazone can be decreased when used in combination with Buprenorphine. |
Isosorbide | Isosorbide The therapeutic efficacy of Isosorbide can be decreased when used in combination with Buprenorphine. |
Clindamycin Injection | Clindamycin Injection The metabolism of Clindamycin can be decreased when combined with Buprenorphine. |
Secobarbital | Secobarbital Secobarbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Desipramine | Desipramine Desipramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Amitriptyline | Amitriptyline The metabolism of Amitriptyline can be decreased when combined with Buprenorphine. |
Imipramine | Imipramine Imipramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Probenecid | Probenecid The metabolism of Buprenorphine can be decreased when combined with Probenecid. |
Quinidine | Quinidine The risk or severity of adverse effects can be increased when Buprenorphine is combined with Quinidine. |
Procainamide | Procainamide The metabolism of Procainamide can be decreased when combined with Buprenorphine. |
Isoniazid | Isoniazid The metabolism of Buprenorphine can be decreased when combined with Isoniazid. |
Rifampin | Rifampin The metabolism of Buprenorphine can be increased when combined with Rifampicin. |
Disopyramide | Disopyramide The risk or severity of adverse effects can be increased when Buprenorphine is combined with Disopyramide. |
Valproic Acid | Valproic Acid Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Tamoxifen | Tamoxifen The metabolism of Tamoxifen can be decreased when combined with Buprenorphine. |
Butabarbital | Butabarbital Butabarbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Levothyroxine | Levothyroxine The metabolism of Buprenorphine can be decreased when combined with Levothyroxine. |
Methimazole | Methimazole The metabolism of Buprenorphine can be decreased when combined with Methimazole. |
Chlorpropamide | Chlorpropamide The metabolism of Buprenorphine can be decreased when combined with Chlorpropamide. |
Tolbutamide | Tolbutamide The metabolism of Tolbutamide can be decreased when combined with Buprenorphine. |
Tolazamide | Tolazamide The metabolism of Buprenorphine can be decreased when combined with Tolazamide. |
Dextromethorphan | Dextromethorphan Dextromethorphan may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Cyclobenzaprine | Cyclobenzaprine Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Niacin | Niacin The metabolism of Buprenorphine can be decreased when combined with Niacin. |
Baclofen | Baclofen Baclofen may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Doxylamine | Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Cyproheptadine | Cyproheptadine Cyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Clemastine | Clemastine Clemastine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Chlorpheniramine | Chlorpheniramine Chlorpheniramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Brompheniramine | Brompheniramine Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Meclizine | Meclizine Meclizine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Methyclothiazide | Methyclothiazide The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Buprenorphine. |
Hydrochlorothiazide | Hydrochlorothiazide The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Buprenorphine. |
Dantrolene | Dantrolene Dantrolene may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Chlorzoxazone | Chlorzoxazone Chlorzoxazone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Carisoprodol | Carisoprodol Carisoprodol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Methocarbamol | Methocarbamol Methocarbamol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Folic Acid | Folic Acid Buprenorphine may decrease the excretion rate of Folic acid which could result in a higher serum level. |
Disulfiram | Disulfiram The metabolism of Buprenorphine can be decreased when combined with Disulfiram. |
Propranolol (Cardiovascular) | Propranolol (Cardiovascular) The serum concentration of Propranolol can be increased when it is combined with Buprenorphine. |
Pseudoephedrine | Pseudoephedrine Pseudoephedrine may increase the analgesic activities of Buprenorphine. |
Nortriptyline | Nortriptyline Nortriptyline may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Spironolactone | Spironolactone The metabolism of Buprenorphine can be decreased when combined with Spironolactone. |
Nadolol | Nadolol The metabolism of Nadolol can be decreased when combined with Buprenorphine. |
Butorphanol Injection | Butorphanol Injection Butorphanol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Nalbuphine Injection | Nalbuphine Injection Nalbuphine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Allopurinol | Allopurinol Buprenorphine may decrease the excretion rate of Allopurinol which could result in a higher serum level. |
Trimethobenzamide | Trimethobenzamide Trimethobenzamide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Flavoxate | Flavoxate The risk or severity of adverse effects can be increased when Buprenorphine is combined with Flavoxate. |
Fluorouracil Injection | Fluorouracil Injection The metabolism of Fluorouracil can be decreased when combined with Buprenorphine. |
Colchicine | Colchicine The metabolism of Colchicine can be decreased when combined with Buprenorphine. |
Cephalexin | Cephalexin The metabolism of Buprenorphine can be decreased when combined with Cephalexin. |
Acetazolamide | Acetazolamide Acetazolamide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Ketoconazole | Ketoconazole The metabolism of Buprenorphine can be decreased when combined with Ketoconazole. |
Pyrantel | Pyrantel Pyrantel may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Thiotepa Injection | Thiotepa Injection The metabolism of Thiotepa can be decreased when combined with Buprenorphine. |
Vincristine Injection | Vincristine Injection The metabolism of Vincristine can be decreased when combined with Buprenorphine. |
Vinblastine | Vinblastine The metabolism of Buprenorphine can be decreased when combined with Vinblastine. |
Ethacrynic Acid | Ethacrynic Acid The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Buprenorphine. |
Metoprolol | Metoprolol The metabolism of Metoprolol can be decreased when combined with Buprenorphine. |
Hydroxyzine | Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Thiothixene | Thiothixene Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Aspirin | Aspirin The metabolism of Acetylsalicylic acid can be decreased when combined with Buprenorphine. |
Alprazolam | Alprazolam The metabolism of Alprazolam can be decreased when combined with Buprenorphine. |
Temazepam | Temazepam Temazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Triazolam | Triazolam Triazolam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Dicyclomine | Dicyclomine The risk or severity of adverse effects can be increased when Buprenorphine is combined with Dicyclomine. |
Hyoscyamine | Hyoscyamine The risk or severity of adverse effects can be increased when Buprenorphine is combined with Hyoscyamine. |
Propantheline | Propantheline The risk or severity of adverse effects can be increased when Buprenorphine is combined with Propantheline. |
Trimethoprim | Trimethoprim The metabolism of Buprenorphine can be decreased when combined with Trimethoprim. |
Diltiazem | Diltiazem The metabolism of Buprenorphine can be decreased when combined with Diltiazem. |
Nifedipine | Nifedipine The metabolism of Buprenorphine can be decreased when combined with Nifedipine. |
Timolol | Timolol The metabolism of Timolol can be decreased when combined with Buprenorphine. |
Verapamil | Verapamil The metabolism of Buprenorphine can be decreased when combined with Verapamil. |
Atenolol | Atenolol The metabolism of Atenolol can be decreased when combined with Buprenorphine. |
Pindolol | Pindolol Pindolol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Cisplatin Injection | Cisplatin Injection The metabolism of Buprenorphine can be decreased when combined with Cisplatin. |
Diflunisal | Diflunisal The metabolism of Buprenorphine can be decreased when combined with Diflunisal. |
Piroxicam | Piroxicam The metabolism of Buprenorphine can be decreased when combined with Piroxicam. |
Bumetanide | Bumetanide The therapeutic efficacy of Bumetanide can be decreased when used in combination with Buprenorphine. |
Etoposide | Etoposide The metabolism of Etoposide can be decreased when combined with Buprenorphine. |
Glyburide | Glyburide Buprenorphine may decrease the excretion rate of Glyburide which could result in a higher serum level. |
Glipizide | Glipizide The metabolism of Glipizide can be decreased when combined with Buprenorphine. |
Indapamide | Indapamide The therapeutic efficacy of Indapamide can be decreased when used in combination with Buprenorphine. |
Pentamidine Injection | Pentamidine Injection The metabolism of Pentamidine can be decreased when combined with Buprenorphine. |
Labetalol | Labetalol The metabolism of Buprenorphine can be decreased when combined with Labetalol. |
Gemfibrozil | Gemfibrozil The metabolism of Buprenorphine can be decreased when combined with Gemfibrozil. |
Ketoprofen | Ketoprofen The metabolism of Buprenorphine can be decreased when combined with Ketoprofen. |
Pimozide | Pimozide Pimozide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Flurbiprofen | Flurbiprofen The metabolism of Buprenorphine can be decreased when combined with Flurbiprofen. |
Amiodarone | Amiodarone The metabolism of Amiodarone can be decreased when combined with Buprenorphine. |
Buspirone | Buspirone The risk or severity of serotonin syndrome can be increased when Buspirone is combined with Buprenorphine. |
Lovastatin | Lovastatin The metabolism of Lovastatin can be decreased when combined with Buprenorphine. |
Ciprofloxacin | Ciprofloxacin The metabolism of Buprenorphine can be decreased when combined with Ciprofloxacin. |
Diclofenac | Diclofenac The metabolism of Buprenorphine can be decreased when combined with Diclofenac. |
Fluoxetine | Fluoxetine Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Clozapine | Clozapine Clozapine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Estazolam | Estazolam Estazolam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Idarubicin | Idarubicin The metabolism of Idarubicin can be decreased when combined with Buprenorphine. |
Clarithromycin | Clarithromycin The metabolism of Buprenorphine can be decreased when combined with Clarithromycin. |
Etodolac | Etodolac The metabolism of Buprenorphine can be decreased when combined with Etodolac. |
Felodipine | Felodipine The metabolism of Buprenorphine can be decreased when combined with Felodipine. |
Nabumetone | Nabumetone The metabolism of Buprenorphine can be decreased when combined with Nabumetone. |
Pravastatin | Pravastatin Buprenorphine may decrease the excretion rate of Pravastatin which could result in a higher serum level. |
Simvastatin | Simvastatin The metabolism of Buprenorphine can be decreased when combined with Simvastatin. |
Teniposide Injection | Teniposide Injection The metabolism of Teniposide can be decreased when combined with Buprenorphine. |
Itraconazole | Itraconazole The metabolism of Buprenorphine can be decreased when combined with Itraconazole. |
Atovaquone | Atovaquone The metabolism of Buprenorphine can be decreased when combined with Atovaquone. |
Rifabutin | Rifabutin The metabolism of Buprenorphine can be increased when combined with Rifabutin. |
Sotalol | Sotalol The metabolism of Sotalol can be decreased when combined with Buprenorphine. |
Zolpidem | Zolpidem Zolpidem may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Doxazosin | Doxazosin The metabolism of Doxazosin can be decreased when combined with Buprenorphine. |
Omeprazole | Omeprazole The metabolism of Buprenorphine can be decreased when combined with Omeprazole. |
Cisapride | Cisapride Cisapride may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Gabapentin | Gabapentin Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Fluvastatin | Fluvastatin The metabolism of Buprenorphine can be decreased when combined with Fluvastatin. |
Venlafaxine | Venlafaxine Venlafaxine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Famciclovir | Famciclovir The metabolism of Buprenorphine can be decreased when combined with Famciclovir. |
Fluvoxamine | Fluvoxamine Fluvoxamine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Nefazodone | Nefazodone Nefazodone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Lamotrigine | Lamotrigine Lamotrigine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Losartan | Losartan The metabolism of Buprenorphine can be decreased when combined with Losartan. |
Tramadol | Tramadol The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Buprenorphine. |
Vinorelbine Injection | Vinorelbine Injection The metabolism of Buprenorphine can be decreased when combined with Vinorelbine. |
Lansoprazole | Lansoprazole The metabolism of Buprenorphine can be decreased when combined with Lansoprazole. |
Ifosfamide Injection | Ifosfamide Injection The metabolism of Buprenorphine can be decreased when combined with Ifosfamide. |
Nicardipine | Nicardipine The metabolism of Buprenorphine can be decreased when combined with Nicardipine. |
Bupropion | Bupropion Bupropion may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Ticlopidine | Ticlopidine The metabolism of Buprenorphine can be decreased when combined with Ticlopidine. |
Saquinavir | Saquinavir The metabolism of Buprenorphine can be decreased when combined with Saquinavir. |
Nisoldipine | Nisoldipine The metabolism of Buprenorphine can be decreased when combined with Nisoldipine. |
Lamivudine | Lamivudine Buprenorphine may decrease the excretion rate of Lamivudine which could result in a higher serum level. |
Riluzole | Riluzole Riluzole may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Glimepiride | Glimepiride The metabolism of Buprenorphine can be decreased when combined with Glimepiride. |
Anastrozole | Anastrozole The metabolism of Buprenorphine can be decreased when combined with Anastrozole. |
Indinavir | Indinavir The metabolism of Buprenorphine can be decreased when combined with Indinavir. |
Ritonavir | Ritonavir The serum concentration of Buprenorphine can be increased when it is combined with Ritonavir. |
Docetaxel Injection | Docetaxel Injection The metabolism of Docetaxel can be decreased when combined with Buprenorphine. |
Clomipramine | Clomipramine Clomipramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Zafirlukast | Zafirlukast The metabolism of Buprenorphine can be decreased when combined with Zafirlukast. |
Mirtazapine | Mirtazapine Buprenorphine may increase the serotonergic activities of Mirtazapine. |
Topiramate | Topiramate Topiramate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Zileuton | Zileuton The metabolism of Buprenorphine can be decreased when combined with Zileuton. |
Valsartan | Valsartan The metabolism of Buprenorphine can be decreased when combined with Valsartan. |
Pramipexole | Pramipexole Buprenorphine may increase the sedative activities of Pramipexole. |
Donepezil | Donepezil Donepezil may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Nelfinavir | Nelfinavir The metabolism of Nelfinavir can be decreased when combined with Buprenorphine. |
Azithromycin | Azithromycin The metabolism of Azithromycin can be decreased when combined with Buprenorphine. |
Loratadine | Loratadine The metabolism of Buprenorphine can be decreased when combined with Loratadine. |
Carvedilol | Carvedilol The metabolism of Carvedilol can be decreased when combined with Buprenorphine. |
Nilutamide | Nilutamide The metabolism of Buprenorphine can be decreased when combined with Nilutamide. |
Flutamide | Flutamide The metabolism of Buprenorphine can be decreased when combined with Flutamide. |
Selegiline | Selegiline The risk or severity of serotonin syndrome and opioid toxicity can be increased when Buprenorphine is combined with Selegiline. |
Bicalutamide | Bicalutamide The metabolism of Buprenorphine can be decreased when combined with Bicalutamide. |
Sertraline | Sertraline Sertraline may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Propafenone | Propafenone The metabolism of Buprenorphine can be decreased when combined with Propafenone. |
Raloxifene | Raloxifene Buprenorphine may decrease the excretion rate of Raloxifene which could result in a higher serum level. |
Irbesartan | Irbesartan The metabolism of Buprenorphine can be decreased when combined with Irbesartan. |
Tamsulosin | Tamsulosin The metabolism of Tamsulosin can be decreased when combined with Buprenorphine. |
Ropinirole | Ropinirole Ropinirole may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Finasteride | Finasteride The metabolism of Finasteride can be decreased when combined with Buprenorphine. |
Quetiapine | Quetiapine Quetiapine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Cetirizine | Cetirizine Cetirizine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Paroxetine | Paroxetine Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Tolcapone | Tolcapone Tolcapone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Citalopram | Citalopram Citalopram may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Capecitabine | Capecitabine The metabolism of Buprenorphine can be decreased when combined with Capecitabine. |
Efavirenz | Efavirenz Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Sildenafil | Sildenafil The metabolism of Buprenorphine can be decreased when combined with Sildenafil. |
Pioglitazone | Pioglitazone The metabolism of Buprenorphine can be decreased when combined with Pioglitazone. |
Celecoxib | Celecoxib The metabolism of Celecoxib can be decreased when combined with Buprenorphine. |
Rosiglitazone | Rosiglitazone The metabolism of Buprenorphine can be decreased when combined with Rosiglitazone. |
Tolterodine | Tolterodine The risk or severity of adverse effects can be increased when Buprenorphine is combined with Tolterodine. |
Thalidomide | Thalidomide Buprenorphine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
Nateglinide | Nateglinide The metabolism of Buprenorphine can be decreased when combined with Nateglinide. |
Galantamine | Galantamine The metabolism of Galantamine can be decreased when combined with Buprenorphine. |
Levetiracetam | Levetiracetam Levetiracetam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Rabeprazole | Rabeprazole The metabolism of Buprenorphine can be decreased when combined with Rabeprazole. |
Terbinafine | Terbinafine The metabolism of Buprenorphine can be decreased when combined with Terbinafine. |
Content provided by: AHFS® Patient Medication Information™. © Copyright, 2021. The American Society of Health-System Pharmacists